Rosiglitazone
Peroxisome Proliferator Receptor gamma Agonist — ALIMENTARY TRACT AND METABOLISM
Also known as: rosiglitazone HCl, rosiglitazone hydrochloride, rosiglitazone maleate, rosiglizole
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Rosiglitazone is an ofm drug in the Peroxisome Proliferator Receptor gamma Agonist class catalogued in DrugCentral. It was first approved by the FDA in 1999. Its mechanism of action is classified as Peroxisome Proliferator-activated Receptor gamma Agonists. DrugCentral lists 23 molecular targets, including Agtr1, Pparg and CISD1. Recorded indications include Treatment Refractory Type 2 Diabetes Mellitus.
- Approval status: ofm (first approved 1999 by the FDA).
- Drug class: Peroxisome Proliferator Receptor gamma Agonist; Thiazolidinedione.
- Mechanism of action: Peroxisome Proliferator-activated Receptor gamma Agonists.
- Molecular targets: Agtr1, Pparg, CISD1 and PPARA (23 listed in DrugCentral).
- Indications: Treatment Refractory Type 2 Diabetes Mellitus.
- ATC code: A10BD03 (Combinations of oral blood glucose lowering drugs).
- Molecular formula: C18H19N3O3S; molecular weight 357.43 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Treatment Refractory Type 2 Diabetes Mellitus
Contraindications (47)
- Acute vomiting
- Adrenal cortical hypofunction
- Alcohol intoxication
- Alcoholism
- Angina pectoris
- Asthenia
- Autonomic dysreflexia
- Body fluid retention
- Breastfeeding (mother)
- Cardiogenic shock
- Cerebrovascular accident
- Chronic heart failure
- Cobalamin deficiency
- Decompensated cardiac failure
- Dehydration
- Disease of liver
- Disorder of coronary artery
- Drug-induced hepatitis
- Fever
- Fever greater than 100.4 Fahrenheit
- Fracture of bone
- Glucose-6-phosphate dehydrogenase deficiency anemia
- Hemolytic anemia
- Hepatic porphyria
- Hypoglycemic disorder
- Hypopituitarism
- Infectious disease
- Ketoacidosis
- Kidney disease
- Lactic acidosis
- + 17 more
Mechanism & targets
| Mechanism of action (MoA) | Peroxisome Proliferator-activated Receptor gamma Agonists |
|---|---|
| Established pharmacologic class | Peroxisome Proliferator Receptor gamma Agonist; Thiazolidinedione |
Molecular targets (23)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Type-1A angiotensin II receptor | Agtr1 | unknown | Ki 9.64 |
| Peroxisome proliferator-activated receptor gamma | Pparg | unknown | EC50 7.52 |
| CDGSH iron-sulfur domain-containing protein 1 | CISD1 | unknown | Ki 7.51 |
| Peroxisome proliferator-activated receptor alpha | PPARA | unknown | EC50 7.41 |
| Peroxisome proliferator-activated receptor alpha | Ppara | unknown | IC50 7.10 |
| Peroxisome proliferator-activated receptor gamma | PPARG | agonist | EC50 7.04 |
| CDGSH iron-sulfur domain-containing protein 1 | Cisd1 | unknown | IC50 5.96 |
| CDGSH iron-sulfur domain-containing protein 2 | CISD2 | unknown | IC50 5.64 |
| Free fatty acid receptor 1 | FFAR1 | agonist | EC50 5.60 |
| Thromboxane-A synthase | TBXAS1 | unknown | IC50 5.45 |
| Peroxisome proliferator-activated receptor delta | PPARD | unknown | EC50 5.44 |
| Carbonic anhydrase 2 | CA2 | unknown | IC50 5.39 |
| Amine oxidase [flavin-containing] B | MAOB | unknown | Ki 5.38 |
| Sodium/bile acid cotransporter | SLC10A1 | unknown | IC50 5.29 |
| Amine oxidase [flavin-containing] B | Maob | unknown | Ki 5.24 |
| Bile salt export pump | ABCB11 | unknown | IC50 5.19 |
| Retinoic acid receptor gamma | RARG | unknown | Ki 5.00 |
| Retinoic acid receptor RXR-alpha | RXRA | unknown | Kd 4.82 |
| Amine oxidase [flavin-containing] A | MAOA | unknown | Ki 4.56 |
| Potassium voltage-gated channel subfamily H member 2 | KCNH2 | unknown | IC50 4.53 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1999-05-25 | FDA | — | SB PHARMCO |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A10BD03 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs |
A10BD04 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs |
A10BG02 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Thiazolidinediones |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Myocardial infarction | 38201.9 |
| Cardiac failure congestive | 36409.3 |
| Coronary artery disease | 18190.0 |
| Cerebrovascular accident | 12664.6 |
| Acute myocardial infarction | 7613.7 |
| Coronary arterial stent insertion | 5255.8 |
| Coronary artery bypass | 4849.5 |
| Angina unstable | 2658.0 |
| Myocardial ischaemia | 2057.9 |
| Vascular graft | 1504.1 |
| Ischaemic cardiomyopathy | 1206.0 |
| Angina pectoris | 1178.4 |
Chemical structure
| Molecular formula | C18H19N3O3S |
|---|---|
| Molecular weight | 357.43 g/mol |
| CAS number | 122320-73-4 |
| InChIKey | YASAKCUCGLMORW-UHFFFAOYSA-N |
| PubChem CID | 77999 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Rosiglitazone used for?
DrugCentral lists the following indications for Rosiglitazone: Treatment Refractory Type 2 Diabetes Mellitus.
How does Rosiglitazone work?
Rosiglitazone is classified as Peroxisome Proliferator-activated Receptor gamma Agonists; its molecular targets in DrugCentral include Agtr1, Pparg, CISD1 and PPARA.
When was Rosiglitazone first approved?
Rosiglitazone was first approved by the FDA in 1999.
What drug class does Rosiglitazone belong to?
Rosiglitazone is in the Peroxisome Proliferator Receptor gamma Agonist class.
What is the chemical formula of Rosiglitazone?
Rosiglitazone has the molecular formula C18H19N3O3S and a molecular weight of 357.43 g/mol.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2405 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL121 — compound record and bioactivity
- PubChem CID 77999 — chemical identifiers
- DrugBank DB00412 — drug record
- FDA UNII 05V02F2KDG — substance identity
- DailyMed: FDA labels for Rosiglitazone — current prescribing information (label search)
- UniProt Q9NZ45 (CISD1) — target protein
- UniProt Q07869 (PPARA) — target protein
- UniProt P37231 (PPARG) — target protein
- UniProt Q8N5K1 (CISD2) — target protein
- UniProt O14842 (FFAR1) — target protein
- UniProt P24557 (TBXAS1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.